New Delhi, July 16, 2018: Lupin on Monday said it had received approval from the U.K. health regulator for its Goa facility.
The facility was inspected by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (UK MHRA) in March 2018 and there were no critical or major observations cited, the pharma major said in a filing with the BSE according to the reports published in thehindu.com.
Lupin MD Nilesh Gupta said: “the outcome of this inspection is a positive and encouraging sign for us, and is a testament to our commitment to maintain global manufacturing standards and best practices.” The approval is a significant development for the company’s Goa plant, the filing added.
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…